Entity

Time filter

Source Type

STOCKHOLM, Sweden

Trademark
Bactiguard Ab | Date: 2009-03-17

Chemical preparations for scientific purposes. pharmaceutical and sanitary preparations and substances, namely, medical preparations, namely, biocompatible surface coating for application to medical devices and drug delivery systems to prevent an adverse response or minimize inflammatory response; antimicrobial and antiseptic preparations and substances; antimicrobial coating for use on medical, surgical and dental equipment devices and instruments to decrease the risk of infection; wound dressings. Surgical apparatus and instruments, surgical implants comprising artificial material and associated surgical instruments sets, implants consisting of artificial materials, medical apparatus, namely, implantable ports; medical tubings for drainage, transfusion and administering drugs, prosthetic and filling materials, namely, artificial materials for use in the replacement of bones; catheters, tubings and parts and fittings therefor; medical apparatus for facilitating the inhalation of pharmaceutical preparations; medical apparatus for introducing pharmaceutical preparations into the human body; medical apparatus, namely, infusion and injection devices for administering drugs; medical apparatus for diagnosing or treating respiratory conditions; surgical and medical apparatus and instruments for use in general surgery; surgical apparatus and instruments for use in ophthalmic surgery; gloves for use in hospitals or for medical purposes.


Grant
Agency: Cordis | Branch: FP7 | Program: BSG-SME | Phase: SME-1 | Award Amount: 1.48M | Year: 2010

The aim of this project is to provide four EU SMEs (Alce Calidad, EASReth, Di.Pro. and Aero Sekur) with a new silver/silica based coating material having anti-septical properties superior to those existing on the market: the coating is made of silica glass and of silver nanoclusters which are embedded in the silica glass. Silica provides excellent thermal and mechanical properties to the coating. The technique used to deposit this coating (RF sputtering) is suitable to almost every kind of substrate (polymers, metals, glasses, etc.). Results will have a clear and immediate exploitation potential to improve or develop new products currently commercialized by the four SMEs : biomedical implants for DiPro, agro/food industry equipments for Alce Calidad and EASReth and personnel protective systems for Aero Sekur. As soon as the anti-septic functionality can be provided to SMEs products, the following new products will be directly put on the market: Di.Pro: new anti-septical artificial anus ALCE and EASReth: new anti-septical coating on surfaces to be used in food handling and processing; Aero Sekur: new anti-septical textiles for Personal Protection Systems (PPS).


Grant
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2011.2.3.1-5 | Award Amount: 3.89M | Year: 2012

Outbreaks of clinical infections affect many thousands of patients in Europe yearly. The present effective treatment for infections is large doses of systemically applied drugs. There is a high risk of recurring infections and biofilm formation for patients dependent on long term in-dwelling catheters and the extended dependency on antibiotics result in clinical drug resistance. We present a new tool for minimizing drug resistance by upgrading existing and future medical devices through a unique self-regenerating surface that prevents biofilm formation by a two-fold stealth attack mechanism. This will be achieved by an interpenetrating polymer network (IPN) that allows for long term release of a range of antimicrobial strategies, such as antimicrobial peptides (AMPs) . The IPNs contain hydrogels where the AMP is stored until the release starts at the insertion of the device with an expected long-term effect. The first line of defence will be a fixed galvanic noble metal alloy coating that will prevent bacteria from colonizing the surface. Local and site-specific treatment with long term effect instead of systemic treatment implies improved patient management and citizen well-fare.


Grant
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.1.3-2 | Award Amount: 8.50M | Year: 2013

Chronic kidney disease is world wide a major cause of end-stage renal disease (ESRD). 800.000 patients in Europe and in the US, respectively, require long-term treatment initially with peritoneal dialysis, followed by hemodialysis and kidney transplantation. Each ESRD patient on hemodialysis costs 40000 to 80000 per year, has extremely poor quality of life and an average life expectancy of only 4 years. Kidney transplantation totally changes life for an ESRD patient who can then return to normal life, but this treatment is hampered by the low number of available kidney grafts. All these treatments are, however, associated with severe adverse reactions that cause damaging thromboinflammation, triggered by the intravascular innate immune system, which lead to poor results and non-function. The overall aim of this project is to clarify the mechanisms and identify natures own specific control points of regulation in these adverse reactions in order to be able to significantly improve the quality of hemodialysis devices and kidney grafts by applying these concepts of regulation in hemodialysis and kidney transplantation. We envisage that conveying a novel soluble complement inhibitor to the clinical stage via phase 1/2a clinical studies, creation of nano-profiled surfaces with low activating properties and generation of easy-to-apply one step-coatings for treatment of biomaterials (hemodialysis) and endothelial cell surfaces (kidney grafts) will revolutionize the treatment modalities of ESRD. The feasible hemodialysis treatment periods are anticipated to be extended, combined with an improved quality of life and in kidney transplantation attenuation of innate immune reactions will prolong the life expectancy of the graft and make kidneys more accessible for transplantation. All the novel techniques can be applied to other types of implantations, extracorporeal treatments and transplantation and in the future be used in xenotransplantation and stem cell therapies.


Trademark
Bactiguard Ab, AD Technology HOLDINGS Ltd and Adhesive Technology International Licensing B.V. | Date: 1997-02-11

antimicrobial coating for use on medical, surgical and dental equipment devices and instruments to decrease the risk of infection, and for use directly on the human body or components of the human body to decrease the risk of infection.

Discover hidden collaborations